Development of a new class of diarylpentadienone analogues as anti-diabetic agents

Type 2 diabetes mellitus (T2DM) is a chronic disease occurred worldwide and is currently a major cause of morbidity and mortality. Several drugs such as sulfonylureas and biguanides are presently available to reduce hyperglycemia in T2DM patients, however, these medicines possess several side eff...

Full description

Saved in:

Bibliographic Details
Main Author:	Abdullah, Maryam Aisyah
Format:	Thesis
Language:	English
Published:	2019
Subjects:	Pharmaceutical chemistry Diabetics - Treatment
Online Access:	http://psasir.upm.edu.my/id/eprint/90036/1/FS%202020%2016%20ir.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-upm-ir.90036
record_format	uketd_dc
spelling	my-upm-ir.900362021-12-03T01:10:28Z Development of a new class of diarylpentadienone analogues as anti-diabetic agents 2019-09 Abdullah, Maryam Aisyah Type 2 diabetes mellitus (T2DM) is a chronic disease occurred worldwide and is currently a major cause of morbidity and mortality. Several drugs such as sulfonylureas and biguanides are presently available to reduce hyperglycemia in T2DM patients, however, these medicines possess several side effects and thus searching for a new class of compounds is essential to overcome this problem. Diarylpentadienone is a synthetic compound derived from curcuminoids and chalconoids, which received less extensive studies by researchers, particularly as anti-diabetic agents. In addition, sulfonamide moiety has proven as essential feature for alpha-glucosidase (α-glucosidase) inhibitors and has potential towards dipeptidyl peptidase 4 (DPP-4) inhibitory activity, the two of therapeutic targets for T2DM treatment. In this study, a series of aminated-1,5-diphenylpenta-2,4-dien-1-ones (compounds 1-9) were synthesized by treating aminoacetophenones with differently substituted cinnamaldehydes via Aldol condensation reaction, further completion by sulfonylation reaction with trifluoromethylbenzenesulfonyl chloride to afford the sulfonamide diarylpentadienone analogues (compounds 10-18). The purified intermediate and final compounds were collected and subjected for confirmatory structural elucidation via established spectroscopic techniques comprising of 1H- and 13C- high field nuclear magnetic resonance (NMR), direct injection-mass spectroscopy (DI-MS), and Fouriertransform infrared (FTIR) spectroscopy. These new integrated sulfonamidediarylpentadienone derivatives were screened for their potential anti-diabetic properties through α-glucosidase and DPP-4 in vitro assay. Based on α-glucosidase inhibition results, all sulfonamide-containing analogues (compound 10-18) showed a remarkable suppression activity, in which compound 18 exhibited the highest inhibition with IC50 values of 4.93 ± 0.7 μM, followed by compound 17 (IC50 = 5.83 ± 0.4 μM), in which both analogues demonstrated good inhibitory activity compared to the standard quercetin (IC50 = 6.38 ± 0.4 μM). The structure-activity relationship (SAR) studies revealed that the introduction of the trifluoromethylbenzene sulfonamide on para position of ring A and a lower electron density group (-Cl) on phenyl ring B of diarylpentadienone scaffold enhanced their α-glucosidase inhibition potential. Molecular docking analyses further confirmed the critical role of both sulfonamide and - Cl moieties as they bound to the α-glucosidase active sites, and thus explain their inhibitory activity. Whereas for DPP-4 inhibition activity, none of the synthesized molecules showed a comparable suppression to the standard drug, sitagliptin, (IC50 = 0.07 ± 0.1 μM). However, within the series, compound 15 showed the most active inhibition with IC50 of 25.05 ± 0.38 μM. The SAR studies showed that the introduction of the trifluoromethylbenzene sulfonamide on para position of ring A and methoxy group on para position on ring B seems to exert a positive influence on the DPP-4 inhibition activity of compound 15. The docking analyses between ligand 15 and DPP-4 receptor (PDB ID:5T4B) showed a hydrogen bonding interaction between sulfonamide moiety with amino acid residues (Tyr574) at the hydrophobic site of the enzyme. Overall results suggest that diarylpentadienone with the sulfonamide moiety could be a new selective potential hit molecule in the search of the novel α-glucosidase inhibitors over anti-DPP-4 agents, for the treatments of T2DM patients. Pharmaceutical chemistry Diabetics - Treatment 2019-09 Thesis http://psasir.upm.edu.my/id/eprint/90036/ http://psasir.upm.edu.my/id/eprint/90036/1/FS%202020%2016%20ir.pdf text en public masters Universiti Putra Malaysia Pharmaceutical chemistry Diabetics - Treatment Mohd. Faudzi, Siti Munirah
institution	Universiti Putra Malaysia
collection	PSAS Institutional Repository
language	English
advisor	Mohd. Faudzi, Siti Munirah
topic	Pharmaceutical chemistry Diabetics - Treatment
spellingShingle	Pharmaceutical chemistry Diabetics - Treatment Abdullah, Maryam Aisyah Development of a new class of diarylpentadienone analogues as anti-diabetic agents
description	Type 2 diabetes mellitus (T2DM) is a chronic disease occurred worldwide and is currently a major cause of morbidity and mortality. Several drugs such as sulfonylureas and biguanides are presently available to reduce hyperglycemia in T2DM patients, however, these medicines possess several side effects and thus searching for a new class of compounds is essential to overcome this problem. Diarylpentadienone is a synthetic compound derived from curcuminoids and chalconoids, which received less extensive studies by researchers, particularly as anti-diabetic agents. In addition, sulfonamide moiety has proven as essential feature for alpha-glucosidase (α-glucosidase) inhibitors and has potential towards dipeptidyl peptidase 4 (DPP-4) inhibitory activity, the two of therapeutic targets for T2DM treatment. In this study, a series of aminated-1,5-diphenylpenta-2,4-dien-1-ones (compounds 1-9) were synthesized by treating aminoacetophenones with differently substituted cinnamaldehydes via Aldol condensation reaction, further completion by sulfonylation reaction with trifluoromethylbenzenesulfonyl chloride to afford the sulfonamide diarylpentadienone analogues (compounds 10-18). The purified intermediate and final compounds were collected and subjected for confirmatory structural elucidation via established spectroscopic techniques comprising of 1H- and 13C- high field nuclear magnetic resonance (NMR), direct injection-mass spectroscopy (DI-MS), and Fouriertransform infrared (FTIR) spectroscopy. These new integrated sulfonamidediarylpentadienone derivatives were screened for their potential anti-diabetic properties through α-glucosidase and DPP-4 in vitro assay. Based on α-glucosidase inhibition results, all sulfonamide-containing analogues (compound 10-18) showed a remarkable suppression activity, in which compound 18 exhibited the highest inhibition with IC50 values of 4.93 ± 0.7 μM, followed by compound 17 (IC50 = 5.83 ± 0.4 μM), in which both analogues demonstrated good inhibitory activity compared to the standard quercetin (IC50 = 6.38 ± 0.4 μM). The structure-activity relationship (SAR) studies revealed that the introduction of the trifluoromethylbenzene sulfonamide on para position of ring A and a lower electron density group (-Cl) on phenyl ring B of diarylpentadienone scaffold enhanced their α-glucosidase inhibition potential. Molecular docking analyses further confirmed the critical role of both sulfonamide and - Cl moieties as they bound to the α-glucosidase active sites, and thus explain their inhibitory activity. Whereas for DPP-4 inhibition activity, none of the synthesized molecules showed a comparable suppression to the standard drug, sitagliptin, (IC50 = 0.07 ± 0.1 μM). However, within the series, compound 15 showed the most active inhibition with IC50 of 25.05 ± 0.38 μM. The SAR studies showed that the introduction of the trifluoromethylbenzene sulfonamide on para position of ring A and methoxy group on para position on ring B seems to exert a positive influence on the DPP-4 inhibition activity of compound 15. The docking analyses between ligand 15 and DPP-4 receptor (PDB ID:5T4B) showed a hydrogen bonding interaction between sulfonamide moiety with amino acid residues (Tyr574) at the hydrophobic site of the enzyme. Overall results suggest that diarylpentadienone with the sulfonamide moiety could be a new selective potential hit molecule in the search of the novel α-glucosidase inhibitors over anti-DPP-4 agents, for the treatments of T2DM patients.
format	Thesis
qualification_level	Master's degree
author	Abdullah, Maryam Aisyah
author_facet	Abdullah, Maryam Aisyah
author_sort	Abdullah, Maryam Aisyah
title	Development of a new class of diarylpentadienone analogues as anti-diabetic agents
title_short	Development of a new class of diarylpentadienone analogues as anti-diabetic agents
title_full	Development of a new class of diarylpentadienone analogues as anti-diabetic agents
title_fullStr	Development of a new class of diarylpentadienone analogues as anti-diabetic agents
title_full_unstemmed	Development of a new class of diarylpentadienone analogues as anti-diabetic agents
title_sort	development of a new class of diarylpentadienone analogues as anti-diabetic agents
granting_institution	Universiti Putra Malaysia
publishDate	2019
url	http://psasir.upm.edu.my/id/eprint/90036/1/FS%202020%2016%20ir.pdf
_version_	1747813603558293504

Development of a new class of diarylpentadienone analogues as anti-diabetic agents

Similar Items